IRMD · XBRL financial data

Iradimed financial statements, every quarter

The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (IRMD's year ends in late December)

In thousands of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue	17,452*	17,598	17,929	18,326	19,389*	19,511	20,409	21,202	22,692*	21,979	20,466	24,203
Revenue from contracts with customers	17,452*	17,598	17,929	18,326	19,389*	19,511	20,409	21,202	22,692*	21,979	20,466	24,203
Cost of revenue	4,039*	4,210	3,919	4,134	4,628*	4,668	4,454	4,708	5,660*	5,165	5,306	5,747
Gross profit	13,413*	13,388	14,010	14,192	14,761*	14,843	15,955	16,494	17,032*	16,814	15,160	18,456
Research and development	650*	3,827	801	639	570*	624	877	674	799*	956	657	875
General and administrative	4,273*	3,991	4,105	3,968	3,873*	4,611	4,280	4,356	4,536*	4,569	3,866	4,533
Total operating expenses	8,253*	8,639	8,383	8,403	8,961*	9,411	9,167	9,661	9,938*	9,577	8,769	10,317
Operating income (loss)	5,160*	4,748	5,627	5,789	5,800*	5,431	6,788	6,834	7,094*	7,237	6,391	8,139
Interest income	year only	—	—	—	year only	—	—	—	year only	—	—	—
Other income (expense)	—	—	—	—	year only	—	—	—	—	—	—	—
Income tax expense (benefit)	1,142*	1,107	1,368	1,369	1,198*	1,258	1,553	1,721	1,349*	1,951	1,670	2,162
Net income (loss)	4,540*	4,137	4,901	5,049	5,147*	4,687	5,774	5,577	6,442*	5,818	5,218	6,506
Earnings per share, basic USD per share	0.36*	0.33	0.39	0.40	0.41*	0.37	0.45	0.44	0.51*	0.46	0.41	0.51
Earnings per share, diluted USD per share	0.36*	0.32	0.38	0.40	0.40*	0.37	0.45	0.43	0.50*	0.45	0.41	0.51
Weighted average shares, basic thousands of shares	12,620*	12,663	12,665	12,670	12,684*	12,714	12,716	12,721	12,737*	12,783	12,784	12,787
Weighted average shares, diluted thousands of shares	12,744*	12,750	12,758	12,778	12,847*	12,826	12,835	12,860	12,894*	12,870	12,872	12,876

Balance sheet

CSV

Fiscal quarters (IRMD's year ends in late December)

In thousands of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	49,762	45,127	48,535	51,721	52,234	50,331	52,996	56,526	51,159	56,374	59,080	63,288
Accounts receivable	12,224	13,027	11,953	10,365	10,557	12,706	10,922	13,858	13,667	13,415	13,192	13,674
Inventory	12,821	12,696	12,071	11,252	10,402	10,556	11,200	11,735	11,620	11,883	12,257	13,487
Prepaid and other current assets	1,193	1,036	1,018	949	2,050	1,544	1,925	1,097	4,757	1,625	1,401	1,251
Total current assets	76,001	71,886	73,578	74,286	75,242	75,137	77,373	84,919	81,203	86,422	86,722	92,800
Property and equipment, net	9,289	9,452	10,473	14,156	16,811	20,378	22,938	23,792	23,856	24,225	24,208	24,076
Right-of-use asset	2,043	1,938	372	264	155	59	—	—	—	—	—	—
Total assets	92,156	88,014	89,949	94,247	98,326	101,729	106,447	114,722	108,776	114,389	114,975	121,070
Accounts payable	1,857	1,285	1,121	1,401	1,896	2,590	1,901	2,333	1,820	2,182	1,849	2,419
Total current liabilities	16,327	7,617	7,458	8,063	8,512	8,473	8,815	12,797	10,180	12,118	9,164	10,323
Lease liability, non-current	1,615	1,520	4	3	1	—	—	—	—	—	—	—
Total liabilities	20,736	11,893	10,278	10,814	11,507	11,675	12,146	16,370	14,158	15,875	13,227	14,616
Retained earnings	43,258	47,395	50,396	53,545	56,791	59,317	62,929	66,343	64,231	67,493	70,154	74,102
Total stockholders' equity	71,420	76,121	79,671	83,433	86,819	90,054	94,301	98,352	94,618	98,514	101,748	106,454
Total liabilities and equity	92,156	88,014	89,949	94,247	98,326	101,729	106,447	114,722	108,776	114,389	114,975	121,070
Common shares outstanding (cover page) thousands of shares	12,663	12,664	12,670	12,673	12,715	12,715	12,720	12,721	12,783	12,783	12,787	12,788

Cash flows

CSV

Fiscal quarters (IRMD's year ends in late December)

In thousands of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	4,540*	4,137	4,901	5,049	5,147*	4,687	5,774	5,577	6,442*	5,818	5,218	6,506
Stock-based compensation	551*	629	609*	630*	657*	826	731*	666*	696*	684	807*	777*
Depreciation and amortization	205*	226	199*	198*	195*	194	207*	384*	381*	455	410*	412*
Net cash from operating activities	3,912*	3,883	6,639*	9,116*	5,987*	4,292	7,746*	6,986*	5,923*	8,290	5,940*	6,997*
Purchases of property and equipment	532*	271	1,134*	3,810*	2,790*	3,697	2,636*	1,138*	294*	403	185*	130*
Net cash from investing activities	(633)*	(479)	(1,270)*	(4,011)*	(3,057)*	(3,917)	(2,824)*	(1,264)*	(416)*	(469)	(443)*	(212)*
Dividends paid	0*	7,976	1,900*	1,900*	1,901*	2,162	2,162*	2,163*	8,554*	2,556	2,557*	2,558*
Net cash from financing activities	(263)*	(8,040)	(1,960)*	(1,918)*	(2,417)*	(2,278)	(2,258)*	(2,192)*	(10,873)*	(2,606)	(2,791)*	(2,577)*
Net change in cash	3,017*	(4,636)	3,408*	3,186*	513*	(1,903)	2,665*	3,530*	(5,367)*	5,215	2,706*	4,208*

Compare with peers

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Iradimed	63,288	24,203	6,997*	12.8M	—	Q3 FY26 10-QSep 30, 2026
Orthofix Medical	103,810	210,933	(6,224)*	40.7M	16.7 quarters	Q2 FY26 10-QJun 30, 2026
Angiodynamics	33,973	80,915	(15,330)	42.1M	2.2 quarters	Q1 FY27 10-QAug 31, 2026
Axogen	328,888	75,834	16,536*	59.7M	—	Q3 FY26 10-QSep 30, 2026
Delcath Systems	47,521	29,133	5,712*	34.7M	—	Q2 FY26 10-QJun 30, 2026
Ceribell	32,663	28,097	(12,863)*	38.4M	10.0 quarters	Q2 FY26 10-QJun 30, 2026
Avanos Medical	65,600	182,200	(12,300)	46.8M	5.3 quarters	Q1 FY26 10-QMar 31, 2026
Cadre Holdings	53,984	207,126	22,131*	42.8M	—	Q2 FY26 10-QJun 30, 2026
Pulse Biosciences	101,620	434	(18,709)*	71.3M	5.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.